Chart, page-1760

Tin hat on, but would anyone support the idea of the company undertaking a modest CR upon commencement of Phase III?

There remains a degree of uncertainty around the timing and nature of first revenues, and in the spirit of being in a position of strength going into partnership negotiations - perhaps a modest CR at these levels would add ballast to the balance sheet, stave off any lingering funding doubts until beyond trial completion, improve their negotiating position with potential partners, and clear the decks of any SP-related risk-factors for new investors aside from Phase III trial success.

Obviously it'd be great if retail holders were well looked after in any raise - but maybe the commencement of Phase III along with the removal of funding doubts, might be the springboard for a genuine re-rate of the stock.

Not pushing for it if it's not necessary - but personally, I wouldn't be too upset if they used this imminent good news to bolster the company's financial position.